Entity
  • Serendip innovations

    Created in 2023
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    1,059
  • Activities

  • Technologies

  • Entity types

  • Location

    12 Rue du Général-Zimmer, 67000 Strasbourg, France

    Strasbourg

    France

  • Employees

    Scale: 2-10

    Estimated: 11

  • Engaged corporates

    4
    1 0
  • Added in Motherbase

    3 weeks, 6 days ago
Description
  • Value proposition

    Development of a nanoparticulate drug delivery system. The high index of modularity allows custom design of medicines.

    Serendip innovations is a preclinical-stage biotechnology company developing an innovative nanoparticulate delivery system for active ingredients. We offer co-development partnerships and licensing of our nanotechnology for applications such as therapeutic and prophylactic vaccination or precision therapies. Our unique value proposition lies in the platform's high degree of modularity, enabling us to custom-design a new class of drugs.
    As a first application, Serendip aims to tackle the challenges of therapeutic vaccines in oncology by turning the platform into a high-performance immunization system to potentiate tumor antigens and trigger robust anti-tumor immune responses. In the cancer vaccine market, Serendip's particle is unique in its ability to precisely target cells of interest.

    In addition to the technical flexibility of the platform, Serendip's plant-based expression system allows the future drug products to be safer, more thermostable; the bioproduction being cost and time effective.

    Our strengths: cell-targeting, immunization, thermostability, bioproduction, modularity and custom design

    Biotechnology, Plant-based Bioproduction, Customised vaccines, Immunology, Oncology, Nanoparticulate drug delivery system, Modularity and custom design, and Cell-targeting

  • Original language

    Development of a nanoparticulate drug delivery system. The high index of modularity allows custom design of medicines.

    Serendip innovations is a preclinical-stage biotechnology company developing an innovative nanoparticulate delivery system for active ingredients. We offer co-development partnerships and licensing of our nanotechnology for applications such as therapeutic and prophylactic vaccination or precision therapies. Our unique value proposition lies in the platform's high degree of modularity, enabling us to custom-design a new class of drugs.
    As a first application, Serendip aims to tackle the challenges of therapeutic vaccines in oncology by turning the platform into a high-performance immunization system to potentiate tumor antigens and trigger robust anti-tumor immune responses. In the cancer vaccine market, Serendip's particle is unique in its ability to precisely target cells of interest.

    In addition to the technical flexibility of the platform, Serendip's plant-based expression system allows the future drug products to be safer, more thermostable; the bioproduction being cost and time effective.

    Our strengths: cell-targeting, immunization, thermostability, bioproduction, modularity and custom design

Corporate interactions BETA
Corporate TypeTweets Articles
Kamet Ventures
Kamet Ventures
Venture Capital and Private Equity Principals
Kamet Ventures
Venture Capital and Private Equity Principals
Other

30 Nov 2024


CNRS
CNRS
Research, Research Services
CNRS
Research, Research Services
Other

6 Jan 2025


BioValley France
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
BioValley France
Public business cluster, Biotechnology, French Cluster, Biotechnology Research
Other

14 Jun 2024


SATT Ouest Valorisation
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
SATT Ouest Valorisation
Research, Startup accelerator & VC, Research Services
Other

30 Nov 2024


Similar entities
Loading...
Loading...
Social network dynamics